CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure

Pharmacogenomics

Volumn 15, Issue 11, 2014, Pages 1423-1435

  Mukonzo, Jackson K ^a,b   Nanzigu, Sarah ^a,b   Waako, Paul ^a   Ogwal Okeng, Jasper ^a   Gustafson, Lars L ^a   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

ABCB1; CYP2B6; efavirenz; HIV; induction; inhibition; isoniazid; pharmacokinetics; rifampicin; Ugandans

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; CREATININE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A5; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; RIFAMPICIN; UREA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYP2B6 PROTEIN, HUMAN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT;

ABCB1 GENE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CYP2B6 GENE; CYP3A5 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EXPOSURE; DRUG INHIBITION; DRUG MONITORING; ENZYME INDUCTION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PHARMACOGENETICS; PRACTICE GUIDELINE; PREDICTIVE VALUE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TUBERCULOSIS; UGANDAN; BLOOD; COINFECTION; GENETICS; HIV INFECTIONS; PROCEDURES;

ADULT; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; COINFECTION; CYTOCHROME P-450 CYP2B6; FEMALE; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; TUBERCULOSIS;

EID: 84907923388     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.73     Document Type: Article

References (48)

1. Steingart KR, Jotblad S, Robsky K, et al. Higher-Dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Tuberc. Lung Dis. 15(3), 305-316 (2011).
2. WHO. HIV/AIDS programme. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2010 revision. http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf
3. Nachega JB, Rosenkranz B, Simon G, Chaisson RE, Diacon A, Taljaard J. Management of adult active tuberculosis disease in era of HIV pandemic, current practices and future perspectives. Infect. Disord. Drug Targets 11(2), 134-143 (2011).
4. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin. Pharmacokinet. 41(9), 681-690 (2002).
5. Rekic D, Roshammar D, Mukonzo J, Ashton M. In silico prediction of efavirenz and rifampicin drug-Drug interaction considering weight and CYP2B6 phenotype. Br. J. Clin. Pharmacol. 71(4), 536-543 (2011).
6. Mukonzo JK, Okwera A, Nakasujja N, et al. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect. Dis. 13, 261 (2013).
7. Ngaimisi E, Mugusi S, Minzi O, et al. Effect of rifampicin and CYP2B6 genotype on long-Term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin. Pharmacol. Ther. 90(3), 406-413 (2011).
8. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516GT polymorphism on efavirenz concentrations in adults in South Africa. Antivir. Ther. 14(5), 687-695 (2009).
9. Ren Y, Nuttall JJ, Eley BS, et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J. Acquir. Immune Defic. Syndr. 50(5), 439-443 (2009).
10. Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur. J. Clin. Pharmacol. 68(5), 689-695 (2012).
11. Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 25(3), 388-390 (2011).
12. Rosenkranz SL, Lu D, Marzan F, et al. Relationship between weight, efavirenz exposure and virologic suppression in HIV-infected patients on rifampin-based TB treatment in the ACTG A5221 STRIDE study. Clin. Infect. Dis. 57(4), 586-593 (2013).
13. Orrell C, Cohen K, Conradie F, et al. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?. Antivir. Ther. 16(4), 527-534 (2011).
14. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308(4), 387-402 (2012).
15. Pozniak AL, Coyne KM, Miller RF, et al British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Med. 12(9), 517-524 (2011).
16. US FDA. Sustiva labeling update/dosing adjustment with rifampin. www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm294476. htm
17. Ngaimisi E, Habtewold A, Minzi O, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS ONE 8(7), e67946 (2013).
18. Habtewold A, Amogne W, Makonnen E, et al. Long-Term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J. Antimicrob. Chemother. 66(10), 2350-2361 (2011).
19. Ngaimisi E, Mugusi S, Minzi OM, et al. Long-Term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin. Pharmacol. Ther. 88(5), 676-684 (2010
20. Mukonzo JK, Roshammar D, Waako P, et al. A novel polymorphism in ABCB1 gene, CYP2B6.6 and sex predict single-Dose efavirenz population pharmacokinetics in Ugandans. Br. J. Clin. Pharmacol. 68(5), 690-699 (2009).
21. Mukonzo JK, Owen JS, Ogwal-Okeng J, et al. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PLoS ONE 9(1), e86919 (2014).
22. Habtewold A, Amogne W, Makonnen E, et al. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenomics J. 13(6), 484-489 (2013).
23. Kunutsor S, Evans M, Thoulass J, et al. Ascertaining baseline levels of antiretroviral therapy adherence in Uganda: a multimethod approach. J. Acquir. Immune Defic. Syndr. 55(2), 221-224 (2010).
24. Tang C, Lin JH, Lu AY. Metabolism-based drug-Drug interactions: what determines individual variability in cytochrome P450 induction?. Drug Metab. Dispos. 33(5), 603-613 (2005).
25. Yenny, Nafrialdi, Djoerban Z, Setiabudy R. Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 49(2), 162-168 (2011).
26. Mukonzo JK, Nanzigu S, Rekic D, et al. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin. Pharmacokinet. 50(8), 531-540 (2011).
27. Lindfelt T, O'Brien J, Song JC, Patel R, Winslow DL. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms. Ann. Pharmacother. 44(10), 1572-1578 (2010).
28. Burger D, Van Der Heiden I, La Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br. J. Clin. Pharmacol. 61(2), 148-154 (2006).
29. Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir. Ther. 13(5), 675-685 (2008).
30. Mcilleron H, Schomaker M, Ren Y, et al. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS 27(12), 1933-1940 (2013).
31. Kwara A, Ramachandran G, Swaminathan S. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin. Drug Metab. Toxicol. 6(1), 55-68 (2010).
32. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, et al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in south India. Antimicrob. Agents Chemother. 53(3), 863-868 (2009).
33. Manosuthi W, Sukasem C, Lueangniyomkul A, et al. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-Drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrob. Agents Chemother. 57(2), 1019-1024 (2013).
34. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J. Antimicrob. Chemother. 58(6), 1299-1302 (2006).
35. Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38(7), 1218-1229 (2010).
36. Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 57(11), 799-804 (2002).
37. Marques MM, Costa MR, Santana Filho FS, et al. Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon. Antimicrob. Agents Chemother. 58(1), 342-347 (2014).
38. Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320(1), 72-80 (2007).
39. Faucette SR, Sueyoshi T, Smith CM, Negishi M, Lecluyse EL, Wang H. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J. Pharmacol. Exp. Ther. 317(3), 1200-1209 (2006).
40. Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet. Genomics 23(8), 415-427 (2013).
41. Swart M, Ren Y, Smith P, Dandara C. ABCB1 4036AG and 1236CT polymorphisms affect plasma efavirenz levels in South African HIV/AIDS patients. Front. Genet, 3, 236 (2012).
42. Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 11(9), 1223-1234 (2010).
43. Nyakutira C, Roshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G-T(.6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur. J. Clin. Pharmacol. 64(4), 357-365 (2008
44. Yimer G, Amogne W, Habtewold A, et al. High plasma efavirenz level and CYP2B6.6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J. 12(6), 499-506 (2012
45. Yimer G, Ueda N, Habtewold A, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS ONE 6(12), e27810 (2011
46. Mugusi S, Ngaimisi E, Janabi M, et al. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS ONE 7(7), e40180 (2012
47. ENCORE1 Study Group; Puls R, Amin J, Losso M, et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 383(9927), 1474-1482 (2014
48. Aklillu E, Dandara C, Bertilsson L, Masimirembwa C Pharmacogenetics of cytochrome P450s in African populations: clinical and molecular evolutionary implications. In: Pharmacogenomics in Admixed Populations. Suarez-Kurtz G (Ed.). Landes Bioscience, TX, USA, 99-119 (2007